↓ Read PDF
01 · ABSTRACT

Abstract

Background: Pancreatic cancer is a highly lethal cancer with no treatment options when diagnosed at an advanced stage. Hapten combined with chemotherapy drugs have been successfully injected into the tumor for local treatment of pancreatic cancer, but due to the heterogeneity of the tumor, the survival time of patients with similar stages is different.

Methods: SCNA-SEQ and Olink proteomics methods were used to observe the cell and genome changes in the survival group treated with hyrazine combined with HEIC for more than 10 months and less than 6 months. scRNA-Seq shows T cell activity of cDCs and polygene-expressed pDCs.

Results: scRNA-Seq confirmed the initiation of immune response: NaiveT and CD8Teff increased, proliferation increased, NK decreased, and ribosomal protein gene upregulated after treatment. The Neutrophils_4 gene set score of precursor cell neutrophilS_4 was higher. There was high expression of interferon-stimulating gene in neutrophils s_3, and high expression of s_3 characteristic gene set in interferon-associated neutrophils. Due to immune action, proteomic results showed that GZMB, GZMZ, IL18, CASP-8, CD8A, HO-1 and AOA genes were up-regulated by 8%. DCN, MCP-1, CX3cl1, CD40, CD27, IL33, TIE2, Gal-9, PGE, MCP-3, CD28, PD-L1, CD38, CCL3, MCP-2, MMP7, laptgf-β-1 genes were down-regulated by 18%.

Conclusions: Overall, the study showed that patients with similar stages of pancreatic cancer had an enhanced immune response after the same regimen of HEIC treatment, and found that gene expression increased by 8% and decreased by 18% in the longer survival group compared with the shorter survival group due to tumor heterogeneity.

↓ Read PDF
02 · PUBLICATION RECORD

Article details

JournalMedical Research Archives
IssueVol 13 No 4 (2025): Vol.13, Issue 4, April 2025
SectionResearch Articles
Published13 May 2025
DOI10.18103/mra.v13i4.6571
ISSN2375-1924
03 · RIGHTS & REUSE

Rights & reuse

This article is published under a Creative Commons Attribution License (CC BY 3.0) and may be shared or distributed by anyone as long as attribution is given to the journal.

Authors & affiliations

BY

Baofa Yu, MD

Immune Oncology Systems, Inc, San Diego, CA, USA, 92102.; TaiMei Baofa Cancer hospital, Dongping, Shandong, China, 271500.; Jinan Baofa Cancer hospital, Jinan, Shandong, China, 250000.; Beijing Baofa Cancer Hospital, Beijing, 100010.

FG

Feng Gao, MD

TaiMei Baofa Cancer hospital, Dongping, Shandong, China, 271500.

PJ

Peng Jing, MD

TaiMei Baofa Cancer hospital, Dongping, Shandong, China, 271500.

GZ

Guoqin Zheng

TaiMei Baofa Cancer hospital, Dongping, Shandong, China, 271500.

Medical Research Archives

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Start your submission  ↗